Dureach

AdvanCell

Australia
NameAddress
Sydney, New South Wales, Australia
https://advancell.com.au

Company profile

AdvanCell company profile

AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. It develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to allow healthcare providers to provide safe and effective treatment for multiple forms of cancer.

Business identity

Website
https://advancell.com.au
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$10K+
Founded
2019-01-01
LinkedInFacebookX

Headquarters

Headquarters
Sydney, New South Wales, Australia
Postal code
2000
Country code
AU
Continent
Oceania

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
4
Total equity funding
$124.5M
Last funding
Grant / $11.3M / 2025-04-13
Last equity funding
Series C / $112M
Investors
9
Lead investors
7
Founders
1
Articles
40

Categories and groups

BiotechnologyClinical TrialsOncologyPharmaceuticalBiotechnologyHealth CareScience and Engineering

Founders and investors

Founders

Andrew Adamovich

Lead investors

AbingworthMedical Research Future Fund (MRFF)MorningsideNSW HealthSanofi VenturesSV Health InvestorsSymBiosis

Investors

AbingworthBrandon CapitalSanofi VenturesSV Health InvestorsSymBiosis

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.